Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial - Vera, Pierre; Thureau, Sébastien; Le Tinier, Florence; Chaumet-Riffaud, Philippe; Hapdey, Sébastien; Kolesnikov-Gauthier, Hélène; Martin, Etienne; Berriolo-Riedinger, Alina; Pourel, Nicolas; Broglia, Jean Marc; Boissellier, Pierre; Guillemard, Sophie; et al. (Lancet Oncology, 2024)